Bavarian Nordic on vaccine candidate: Preclinical data indicates broad protection

Preclinical data on Bavarian Nordic's covid-19 vaccine candidate indicates broad protection, the company reports on Thursday.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

In a press release on Thursday morning, Danish biotech company Bavarian Nordic states that new preclinical trial data indicates that the firm's vaccine candidate against covid-19 also has the ability to induce a high number of neutralizing antibodies against covid variants and mutations.

"We are pleased to confirm the strong antibody response against emerging and more concerning variants of Sars-CoV2 for our covid-19 vaccine candidate," says Bavarian Nordic CEO Paul Chaplin the statement.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs